Report cover image

Pharmaceutical Clinical Contract Peripheral Services, Global, 2025–2030

Publisher Frost & Sullivan
Published Mar 21, 2025
SKU # MC19877998

Description

As trial volumes normalize after the COVID-19 pandemic, pharma and biopharma companies are re-focusing on their drug development pipelines. As a result, the market has been creating an increasing number of clinical trial outsourcing opportunities for CROs, with these service providers also refining their processes to ensure better clinical trial turnarounds and improved time to market. In this context, the global CRO industry was valued at $66.39 billion in 2024, and it is expected to register a CAGR of 10.7% from 2024 to 2030, reaching $122.13 billion in 2030. Across the global pharma market, the overall CRO outsourcing penetration rate ranges from 45%-50%, depending on the service type.

In addition to full-service CROs operating in the global CRO industry, there is a surge of peripheral service-focused CROs, also referred to as specialized/niche CROs. These companies exclusively focus on supportive functions, including biostatistics, lab testing, pharmacovigilance, post-market surveillance, and investigational product (IP) management. These activities support the core clinical research functions, ensuring timely completion and required outcomes.

As the emphasis on biologics drug development grows, small-to-mid-sized and emerging biopharma companies are contributing more than 50% of the pipelines. Apart from trial-related services, such as patient recruitment, site selection and management, and investigator recruitment, clinical trial peripheral services, such as pharmacovigilance, safety testing, central lab services, medical writing, IP management, data management, and biostatistics, have been gaining traction, with pharma sponsors increasingly outsourcing these specific activities to CROs.

This is leading to the extensive use of the functional service provider (FSP) model targeting specific trial-related ancillary or peripheral activities. Though a significant share of the clinical pipeline is contributed by small-to-mid-sized and emerging biopharma companies, the need for peripheral services through FSP models is expected to witness a sharp rise, especially from large pharma companies looking to optimize trial costs.

Moreover, the industry will witness a shift to a hybrid FSO/FSP model, as companies aim to augment their clinical trial activities through better risk mitigation. As a result, these companies will look for outsourcing partners to meet their clinical research needs, paving the way for both full-service outsourcing and FSP models, which focus on supporting peripheral activities, such as analytical testing, data management, and biostatistics.

Key Issues Addressed
What are the general industry trends? What are the specific trends for peripheral activities within clinical trials?
What are the key drivers triggering large-scale outsourcing of clinical development?
What key emerging business models are providing a competitive advantage to pharma sponsors? How is this trend supporting industry convergence?
Who are the leading participants driving market growth?
What is the growth opportunity for small-to-mid-sized CRO companies amidst 1,500+ competitors?
How is the application of technology supporting the growth of the CRO peripheral activities landscape? Which are the fastest-growing peripheral activities in the CRO industry?

Table of Contents

    • Scope of Analysis
    • Segmentation
    • CRO Peripheral Services-Defining Key Activities Across Peripheral Services
    • Why Is It Increasingly Difficult to Grow?
    • The Strategic Imperative 8TM
    • The Impact of the Top 3 Strategic Imperatives on the Pharmaceutical Clinical Contract Peripheral Services Industry
    • Market Trend Analysis
    • Contract Peripheral Services-Vendor Ecosystem
    • CRDMO-The New Normal in Early-stage Drug Development
    • Evolving Partnership Models Across the CRO Market
    • FSP Model Types
    • FSP Model Outlook
    • Competitive Environment
    • Key Competitors-By Regions
    • Investment Trends
    • Portfolio Expansion with M&As
    • Project-specific CRO Expertise With Strategic Partnerships
    • In-house Investments for Long-term Growth
    • Growth Metrics
    • Growth Drivers
    • Growth Restraints
    • Forecast Assumptions
    • Market Forecast-Limitations and Caveats
    • Revenue Forecast Methodology
    • Revenue Forecast
    • Revenue Forecast Analysis
    • Revenue Forecast by Clinical Development Phase
    • Percent Revenue Share by Clinical Development Phase
    • Revenue Forecast Analysis by Clinical Development Phase
    • Revenue Share
    • Revenue Share Analysis
    • Revenue Forecast by Region
    • Percent Revenue Forecast by Region
    • Revenue Forecast Analysis-North America
    • Revenue Forecast Analysis-Europe
    • Revenue Forecast Analysis-APAC
    • Revenue Forecast Analysis-LATAM and Caribbean
    • Revenue Forecast Analysis-MEA
    • Revenue Forecast by Peripheral Services Versus Core Services
    • Percent Revenue Forecast by Peripheral Services Versus Core Services
    • Revenue Forecast by Peripheral Service Segments
    • Revenue Forecast Analysis
    • Central Lab Testing Services
    • Central Lab Testing Services-Revenue Forecast
    • Central Lab Testing Services-Revenue Forecast by Region
    • Central Lab Testing Services-Revenue Forecast Discussion
    • Biostatistics Services
    • Biostatistics Services-Revenue Forecast
    • Biostatistics Services-Revenue Forecast by Region
    • Biostatistics Services-Revenue Forecast Discussion
    • Data Management Services
    • Data Management Services-Revenue Forecast
    • Data Management Services-Revenue Forecast by Region
    • Data Management Services-Revenue Forecast Discussion
    • Pharmacovigilance and Safety Testing Services
    • Pharmacovigilance and Safety Testing Services-Revenue Forecast
    • Pharmacovigilance and Safety Testing Services-Revenue Forecast by Region
    • Pharmacovigilance and Safety Testing Services-Revenue Forecast Discussion
    • IP Management Services
    • IP Management Services-Revenue Forecast
    • IP Management Services-Revenue Forecast by Region
    • IP Management Services-Revenue Forecast Discussion
    • Medical Writing Services
    • Medical Writing Services-Revenue Forecast
    • Medical Writing Services-Revenue Forecast by Region
    • Medical Writing Services-Revenue Forecast Discussion
    • Regulatory and Medical Affairs Services
    • Regulatory and Medical Affairs Services-Revenue Forecast
    • Regulatory and Medical Affairs Services-Revenue Forecast by Region
    • Regulatory and Medical Affairs Services-Revenue Forecast Discussion
    • Growth Opportunity 1: Medical Co-pilot-powered Clinical Trial Data Management
    • Growth Opportunity 2: Central Lab Services for Biotechnology Companies in Australia
    • Growth Opportunity 3: Customized Services for Regulatory and Medical Affairs
    • Growth Opportunity 4: Pharmacovigilance-as-a-Service
    • Growth Opportunity 5: Customer-centric Partnership Models for Peripheral Service Outsourcing
    • Benefits and Impacts of Growth Opportunities
    • Next Steps
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.